Lab Team

Dr. Caldas-Lopes is a pharmacologist scientist dedicated to study mechanisms of drug resistance and response as well as the biology of B-cell lymphomas. She studies the role of novel transcription factors acting as tumor supressors in NF-kB-driven aggressive lymphomas that are refractory to standard treaments. She also studies how this lymphomagenic process decreases lymphoma immunity and shapes the lymphoma microenvironment. She conducts correlative studies in clinical trials involving B-cell amd T-cell lymphoma patients treated with epigenetic drugs, targeted agents and immunotherapeutic approaches. 

He studies the interaction between different cells of the microenvironment with lymphoma cells to understand the role of the lymphoma microenvironment (LME) in the progression of this disease and how this information can be used for development of innovative treatments for patients with B-cell and T-cell lymphomas. He is focusing in the role of cancer-associated fibroblasts and tumor associated macrophages in sustaining lymphoma cells while decreasing lymphoma immunity. Employing an array of techniques and innovative animal models, he developed therapeutic approaches based primarily in targeting the LME.

She studies computational biology in B-cella and T-cell lymphomas with emphasis in transcriptomics, metabolomics, DNA methylomics and proteomics. She applies a vast array of bioinformatic tools to the analysis of pre-clinical models and patient samples including single-cell "omics". Her reserach interest includes the cell-cell communication of microenvironment and cancer cell in lymphomas and how this intreaction induces transcriptional and epigenetic changes. She design and analysis samples from clinical trials to develop pharmacodynamic and patient-selection biomarkers to increase the precision of novel therapeutic approaches. Her research focuses in understanding how biological traits contribute to health disparities in lymphoma patients including geriatric populations.

His research interest focuses in the role of mitochondria physiology and pathology in the maintenance of B-cell lymphomas, particularly in the events leading to disease progression. He study how metabolites and other mitochondria-derived products shape the lymphoma microenvironment (LME) for disease progression and to decrease lymphoma immunity and how these pathways can be capitalized for therapeutic gain and increase the effect of immunotheraputic approaches. 

* Dr. Rossella Marullo (Italy).  DNA damage in lymphoma, XPO1 biology, cancer metabolism in radiosensitization. Currently Medical Director at Regneron. New York. 

* Dr. Erin Mulvin (US).  T-cell and B-cell lymphomas, geriatric oncology. Currently Hematology Oncology Attending - NYPH- WCM, New York  

* Dr. Jude Phillip (Grenada-US).  Physics of T-cell and B-cell lymphomas. Currently Assistant Professor of Biomedical Engineering at Johns Hopkins University. Baltimore.  

* Dr. Jan Krumsiek (Germany): Bioinformatics in Metabolomics. Currently Assistant Professor at Weill Conell Medicine. New York City.

* Dr. Benet Pera Gresely (Spain): Epigenetic-based targeting of B-cell lymphomas. Currently Advisor in the investment bank Mizuho Securities, Inc. New York City. 

* Dr. M. Nieves Calvo-Vidal (Spain): Metabolism of lymphomas. Currently Scientist Cancer Knowledge Base at sema4. Stamford, CT.

* Dr. Ildefonso Rodriguez-Rivera (U.S.): Biomarkers for B-cell lymphoma. Currently Attending Physician at Memorial Sloan Kettering Cancer Center, New York City.

* Dr. Mariano Cardenas (Argentina): Experimental therapeutics in B-cell lymphomas. Currently Research Support Specialist at the Rockefeller University, New York City

* ShaoNing Yang (Taiwan-U.S.): Experimental pharmacology. Currently Research Associate IV at Regeneron Pharmaceuticals, Inc. New York.

* Dr. Lidia Roman (Spain): Drug screening, assay development and clinical trial coordination. Currently Scince Project Manager, Janssen Vaccines, Johnson&Johnson, The Netherlands.

* Dr. Florencia Cayrol (Argentina): Pathology and experimental pharmacology of peripheral T-cell lymphomas and cutaneous lymphomas. Currenlty Research Scientist CONICET Argentina.

* Dr. Mariangeles Clauzure (Argentina): Radiosensitizers in breast canecr. Currenlty Research Scientist CONICET Argentina.

* Jayeshkumar Patel (India): Lymphoma metabolism.

* Haelee Ahn (South Korea): Lymphoma 3D organoids.

* Dr. Florencia Aizpurua (Argentina): Hematooncologist focusing in B-cell lymphomas. Currently Hemato-oncologist, Hospital Aleman, Buenos Aires.

* Dr. Pannee Praditsuktavorn (Thailand): Experimental Therapeutics in T-cell lymphomas. Currently Assistant Professor and Attending at the Chulabhorn Royal Academy Hospital, Bangkok

* Dr. Kaipol Takpradit (Thailand): Hematoocologist focusing in T-cell lymphomas. Currently Attending physician at the Chulabhorn Royal Academy Hospital, Bangkok

* Dr. Tyffany Tang (Singapore): Hematooncologist focusing in T-cell lymphomas.  Currently Attending physician at the National Cancer Institute of Singapore.

* Dr. Pablo Cresta Morgado (Argentina): Clinical Oncologist focusing in cervical cancer and brain metastases. Currently chief of Fellows at the Instituto Roffo, Buenos Aires..

* Dr. Thomas Clozel (France): Hematooncologist focusing in B-cell lymphomas. Currently co-founder and CEO of biotech company OWKIN

* Dr. Thibault Dupont (France): PhD and medical student with interest in lymphoma metabolism.

* Dr. Franco Izzo (Argentina): Role of hormones in breast cancer. Currently postdoctoral associate at Weill Cornell Medicine, New York City.

* Dr. Charles McTavish (U.S.): American Society of Hematology HONORS Awardee. Focusing in double-hit lymphomas. 

 Graduate Students:

Rebecca Goldstein (U.S.). Weill Cornell Graduate School. Pharmacology Department.

Tharu Fernando (U.S.). Weill Cornell Graduate School. Pharmacology Department.

Edd Ricker (U.S.). Weill Cornell Graduate School. Pharmacology Department and Hospital for Special Surgery.